Strengths

Cash and near-cash liquidity appears adequate versus smaller peers, with a 2.55 current ratio and 1.51 quick ratio supporting short-term resilience.

Negative net debt to EBITDA indicates limited leverage pressure versus more indebted peers, which can preserve flexibility during demand volatility.

The company’s capital structure is less constrained than highly levered medtech peers, reducing refinancing risk and supporting operating continuity.

Despite weak profitability, the balance sheet provides a modest buffer that can help absorb working-capital swings better than cash-strained competitors.

Weaknesses

ROIC of -1.19% shows capital is not earning its cost, leaving RPID structurally behind profitable peers on value creation.

A 215.7-day cash conversion cycle ties up working capital far longer than efficient peers, which suppresses liquidity and operating flexibility.

Debt-to-equity of 1.32 is elevated for a company with negative returns, making the capital structure less forgiving than low-leverage peers.

The absence of reported operating and gross margin strength suggests the business lacks the durable profitability profile that stronger peers use to compound scale.

Opportunities

If working capital efficiency improves, the long cash conversion cycle could release cash faster than peers with similarly small revenue bases.

A stronger balance-sheet position than highly levered peers creates room to fund commercialization or product development without immediate financing stress.

Any sustained improvement in returns on invested capital would have outsized impact because current peer positioning starts from a low profitability base.

Relative upside exists if management narrows the gap to better-capitalized medtech peers through tighter inventory, receivables, and payables discipline.

Threats

Persistent negative ROIC leaves RPID vulnerable to peers that can reinvest at positive returns, widening the structural performance gap over time.

The long cash conversion cycle increases exposure to funding needs, especially versus peers that convert sales to cash more quickly.

Higher debt-to-equity can become a disadvantage if operating losses persist, because peers with cleaner balance sheets retain more strategic flexibility.

In a competitive medtech market, weaker profitability and working-capital efficiency can limit pricing power relative to peers with stronger execution.

Overall Score

RPID’s peer positioning is weak overall because negative returns and inefficient working capital outweigh its modest liquidity and limited net leverage advantages.